FDA guidance on conducting trials during emergencies shifts away from COVID-19
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsComplianceMedical DevicesNorth AmericaPharmaceuticalsProject managementRegulatory Intelligence/Policy